Male Hypogonadism – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Male Hypogonadism – Pipeline Review, H1 2018’, provides an overview of the Male Hypogonadism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Male Hypogonadism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Male Hypogonadism

– The report reviews pipeline therapeutics for Male Hypogonadism by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Male Hypogonadism therapeutics and enlists all their major and minor projects

– The report assesses Male Hypogonadism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Male Hypogonadism

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Male Hypogonadism

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Male Hypogonadism pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Antares Pharma Inc

Clarus Therapeutics Inc

EndoCeutics Inc

Ferring International Center SA

Lipocine Inc

M et P Pharma AG

Medlab Clinical Ltd

Merck & Co Inc

Mereo Biopharma Group Plc

Repros Therapeutics Inc

TesoRx Pharma LLC

Viramal Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Male Hypogonadism Overview

Male Hypogonadism Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Male Hypogonadism Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Male Hypogonadism Companies Involved in Therapeutics Development

Antares Pharma Inc

Clarus Therapeutics Inc

EndoCeutics Inc

Ferring International Center SA

Lipocine Inc

M et P Pharma AG

Medlab Clinical Ltd

Merck & Co Inc

Mereo Biopharma Group Plc

Repros Therapeutics Inc

TesoRx Pharma LLC

Viramal Ltd

Male Hypogonadism Drug Profiles

BGS-649 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corifollitropin alfa Drug Profile

Product Description

Mechanism Of Action

R&D Progress

enclomiphene citrate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IAS-167A Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kisspeptin-10 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leuprolide acetate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Libidua Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LPCN-1111 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone enanthate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone propionate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VERU-722 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Male Hypogonadism Dormant Projects

Male Hypogonadism Discontinued Products

Male Hypogonadism Product Development Milestones

Featured News & Press Releases

Jan 10, 2018: Lipocine Announces Outcome of FDA Advisory Committee Meeting for TLANDO, Testosterone Replacement Therapy in Adult Males with Hypogonadism

Dec 15, 2017: Repros Therapeutics Receives Feedback Following an Oral Explanation with the European Medicines Agency

Dec 06, 2017: Acerus Enters into Loan Facility to Support Anticipated Product Launch and Sales and Marketing Initiatives

Nov 30, 2017: Acerus Secures CDN$1.6M of New NATESTO Orders from Its U.S. Licensee Aytu Bioscience

Nov 28, 2017: Aytu BioScience Provides Update on the Continued Growth of Natesto in the U.S.

Nov 17, 2017: U.S. FDA Extends Review for TLANDO; Advisory Committee Meeting Date of January 10, 2018 Remains Unchanged

Oct 26, 2017: Aytu BioScience Provides Quarterly Update on the Natesto U.S. Launch

Oct 18, 2017: FDA Advisory Committee Scheduled to Review TLANDO on January 10, 2018

Sep 26, 2017: Aytu BioScience Provides Update on the Natesto U.S. Launch

Sep 20, 2017: Lipocine Announces FDA Advisory Committee Meeting for TLANDO

Sep 05, 2017: Completion of Patient Enrolment in Phase 2b dose-confirmation study of BGS-649 for the treatment of hypogonadotropic hypogonadism

Aug 14, 2017: Lipocine Announces FDA Acknowledgement of TLANDO (“LPCN 1021”) NDA Resubmission; PDUFA Goal Date, February 8, 2018

Aug 09, 2017: Lipocine Resubmits NDA for Its Oral Testosterone Product Candidate, LPCN 1021, for Treatment of Hypogonadism

Jun 26, 2017: Clarus Re-submits JATENZO NDA Following Positive Results of inTUne Trial

Jun 19, 2017: Lipocine to Host Conference Call and Webcast to Discuss Top-Line Results From the Dosing Validation and Dosing Flexibility Studies of LPCN 1021

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Male Hypogonadism, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Male Hypogonadism Pipeline by Antares Pharma Inc, H1 2018

Male Hypogonadism Pipeline by Clarus Therapeutics Inc, H1 2018

Male Hypogonadism Pipeline by EndoCeutics Inc, H1 2018

Male Hypogonadism Pipeline by Ferring International Center SA, H1 2018

Male Hypogonadism Pipeline by Lipocine Inc, H1 2018

Male Hypogonadism Pipeline by M et P Pharma AG, H1 2018

Male Hypogonadism Pipeline by Medlab Clinical Ltd, H1 2018

Male Hypogonadism Pipeline by Merck & Co Inc, H1 2018

Male Hypogonadism Pipeline by Mereo Biopharma Group Plc, H1 2018

Male Hypogonadism Pipeline by Repros Therapeutics Inc, H1 2018

Male Hypogonadism Pipeline by TesoRx Pharma LLC, H1 2018

Male Hypogonadism Pipeline by Viramal Ltd, H1 2018

Male Hypogonadism Dormant Projects, H1 2018

Male Hypogonadism Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Male Hypogonadism, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports